Glox Therapeutics
- Biotech or pharma, therapeutic R&D
Glox Therapeutics is developing engineered novel protein antibiotics based on protein bacteriocins (PBs). Unlike conventional antibiotics, bacteriocins are highly specific, targeting individual pathogens while sparing the surrounding microbiome. This precision preserves the beneficial functions of the microbiome, including its crucial role in protecting against secondary infections—a common side effect of broad-spectrum antibiotic use. Glox is initially targeting highly antibiotic-resistant pathogens, in ventilator and hospital acquired pneumonia (HAP/VAP including Pseudomonas aeruginosa, E. coli and Klebsiella pneumoniae.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}